Business Context and Reporting Period
This Form 8-K, dated April 1, 2026, reports a corporate reorganization by Senti Biosciences, Inc. (the "Company"). The Company announced plans to implement a holding company reorganization, currently scheduled to become effective by April 16, 2026.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the structural reorganization of the company.
Material Changes
- Corporate Structure: The Company will merge with and into Senti Biosciences Merger Sub, Inc., a subsidiary of Senti Holdings, Inc., which is a subsidiary of Senti Biosciences Holdings, Inc. (a wholly owned subsidiary of the Company).
- Successor Issuer: Upon effectiveness, Senti Biosciences Holdings will become the successor issuer to the Company.
- Share Conversion: Each share of Company Common Stock will automatically convert into one share of Senti Biosciences Holdings Common Stock with identical rights and preferences.
- Trading Continuity: The new common stock will continue to trade on the Nasdaq Capital Market under the symbol "SNTI" with a new CUSIP number.
- Management Continuity: Directors and executive officers will remain the same with unchanged titles and responsibilities.
Guidance, Outlook, and Risks
- Tax Implications: The reorganization is structured as a tax-free merger; stockholders will not recognize gain or loss for U.S. federal income tax purposes upon conversion.
- Procedural Mechanism: The reorganization will be conducted under Section 251(g) of the Delaware General Corporation Law, requiring no stockholder vote.
- Risks and Contingencies: The Company may decide not to implement the reorganization, or completion could be delayed beyond the anticipated timeframe due to factors beyond the Company's control.
Investor Verification Checklist
- Confirm the effective date of the reorganization (currently planned for April 16, 2026).
- Verify the new CUSIP number for the Senti Biosciences Holdings Common Stock.
- Monitor for any announcements regarding delays or cancellation of the reorganization.
- Ensure brokerage accounts reflect the automatic conversion of shares without requiring investor action.